To Study Comparative Efficacy and Safety of Thrombolytics (Streptokinasev / Stenecteplase) Based on ECG Changes in Stemi Patients

Dr. Pradeep Kumar, Dr. Badrinath Bhougal

Abstract: This prospective observational study evaluates and compares the efficacy and safety of two thrombolytic agents, Streptokinase and Tenecteplase, in patients presenting with ST-Elevation Myocardial Infarction (STEMI) at GMC Kathua. A total of 100 patients were included, divided equally between the two treatment groups. The assessment focused on electrocardiographic changes, symptom relief timing, and incidence of adverse effects following thrombolytic therapy. Findings showed a greater proportion of patients in the Tenecteplase group achieving ST-segment resolution above 50% and higher early symptom relief rates. Additionally, Tenecteplase was associated with fewer complications, including zero reported cases of cardiogenic shock, arrhythmia, anaphylaxis, or stroke/bleeding, while the Streptokinase group reported multiple adverse outcomes. Despite comparable baseline characteristics and risk factors across both groups, Tenecteplase demonstrated a more favorable safety and efficacy profile. These results highlight its clinical potential in scenarios where primary PCI is not immediately available.

Keywords: STEMI, thrombolytic therapy, Streptokinase, Tenecteplase, ECG changes

How to Cite?: Dr. Pradeep Kumar, Dr. Badrinath Bhougal, "To Study Comparative Efficacy and Safety of Thrombolytics (Streptokinasev / Stenecteplase) Based on ECG Changes in Stemi Patients", Volume 14 Issue 12, December 2025, International Journal of Science and Research (IJSR), Pages: 890-896, https://www.ijsr.net/getabstract.php?paperid=MR251209161316, DOI: https://dx.doi.org/10.21275/MR251209161316